Citius Pharmaceuticals Inc (47N.DU)
Chart Events
Performance Outlook
| Previous Close | 0.8952 |
| Open | 0.8952 |
| Bid | 0.9097 x N/A |
| Ask | 0.9339 x N/A |
| Day's Range | 0.9125 - 0.9125 |
| 52 Week Range | 0.7227 - 1.9982 |
| Volume | |
| Avg. Volume | 63 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 47N.DU
Related Research
- PR Newswire
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB.
- PR Newswire
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California. Citius Chairman and CEO Leonard Mazur will host one-on-one meetings with institutional investors and analysts on Monday, March 13th and Tuesday, March 14th.
- PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2022.
